CN115414325A - Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof - Google Patents
Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof Download PDFInfo
- Publication number
- CN115414325A CN115414325A CN202210912990.0A CN202210912990A CN115414325A CN 115414325 A CN115414325 A CN 115414325A CN 202210912990 A CN202210912990 A CN 202210912990A CN 115414325 A CN115414325 A CN 115414325A
- Authority
- CN
- China
- Prior art keywords
- silver
- nano
- nasal cavity
- solution
- cavity nursing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention relates to a nano-silver nasal cavity nursing sterilizing liquid, a preparation method and application thereof. A nano silver nasal cavity nursing sterilizing liquid comprises the following raw materials; nano silver particle stock solution (10000 ppm), carboxymethyl cellulose, deionized water and shellGlycan, naCO 3 The selected A nano silver particles have the following properties: the silver particles have individual particle size of 2-10nm, wherein 80% of the particle diameter<5nm, the surfaces of the silver particles are wrapped by the dispersing agent, so that the silver particles are prevented from being oxidized and losing efficacy in the air, and meanwhile, the nano silver particles can be smoothly released after the dispersing agent is dissolved in the water body. The nasal cavity nursing sterilizing liquid adopts nano silver for sterilization, has the advantages that the nano silver nasal cavity nursing sterilizing liquid solution is an effective medicament for treating rhinitis and nasosinusitis, has the total effective rate of 96.7 percent, has good effect on recovery after nasal cavity operation and laser and plasma treatment, and has better curative effect than a control group. The nano-silver antibacterial solution adopts a spray administration mode, directly takes effect on focus, does not need in vivo conversion, and avoids adverse reaction. Has no obvious adverse reaction in clinical use, and is also suitable for children.
Description
Technical Field
The invention relates to nano-silver nasal cavity nursing sterilization, a preparation method and application thereof, in particular to nano-silver nasal cavity nursing sterilization liquid applied to the personal care industry.
Background
Allergic Rhinitis (AR) is also called as allergic rhinitis, belongs to nasal mucosa allergic diseases, is mainly characterized by increased nasal mucosa reactivity, is clinically mainly manifested by paroxysmal sneezing, watery nasal discharge, nasal obstruction and nasal itching and is partially accompanied by hyposmia, wherein nearly 40 percent of patients with allergic rhinitis can be combined with bronchial asthma and simultaneously can be accompanied by pulmonary symptoms such as wheezing, coughing, shortness of breath, chest distress and the like, the life quality, the sleep quality, the mood, the working efficiency and the like of the patients are directly influenced, heavy mental and psychological burden is brought to the patients, and the normal life of the patients is influenced. At present, the global allergic rhinitis patients account for 20-30% of the total population, the morbidity of China is also in a remarkable rising trend in recent years, the attention of scholars is attracted, and the method is a public health and social medical problem to be solved urgently.
For allergic rhinitis, the commonly used drug therapy mainly comprises the following seven aspects: (1) Oral or nasal antihistamine, present common use include loratadine, cetirizine, olopatadine, rupatadine, etc., nasal antihistamine common use azelastine hydrochloride nasal spray, etc.; (2) Glucocorticoid can inhibit the generation and release of inflammatory mediators, inhibit the activity and the number of immune cells participating in inflammatory reaction, and improve the tolerance of organisms to toxin, and commonly used medicaments such as mometasone furoate (endoxat), fluticasone propionate (syndesmopram), budesonide (Renide), beclomethasone dipropionate (Berkelin) and the like can effectively relieve symptoms such as nasal obstruction, watery nasal discharge, sneeze and the like, and the currently applied glucocorticoid nasal spray is one of internationally accepted effective treatment methods; (3) Anti-leukotriene, namely leukotriene receptor antagonist, comprising montelukast, zafirlukast and prussist, blocks the action of cysteinyl leukotriene by competitively binding cysteinyl leukotriene receptor, and relieves symptoms of nasal obstruction, watery nasal discharge, sneeze, rhinocnesmus, etc.; (4) The chromone medicine has certain effect on relieving nasal symptoms, and the eye drops have certain effect on relieving eye symptoms; (5) The nasal decongestant has sympathomimetic activity, can contract blood vessels of nasal mucosa by nasal administration, reduce the swelling of tissues, effectively relieve nasal obstruction caused by nasal congestion, improve nasal ventilation, and is often used together with antihistamines, but because the medicines can cause rebound nasal congestion, the medicines have adverse reactions to heart and cerebral vessels and mainly show irritability, dizziness, headache, insomnia, tachycardia, hypertension and the like, the nasal decongestant is only suitable for treatment with short treatment course and is controlled within seven days, and the nasal decongestant is not recommended to be used in long-term treatment of allergic rhinitis; (6) The intranasal anticholinergic medicament can effectively inhibit running nose, and is not obvious in treatment of other symptoms, so that the application range is narrow; (7) The traditional Chinese medicine is effective in relieving partial symptoms, but the use of the traditional Chinese medicine is not recommended due to unclear action mechanism.
Disclosure of Invention
The invention aims to provide a nano-silver nasal cavity nursing and sterilizing liquid, a preparation method and application thereof.
In order to solve the technical problems, the technical scheme of the invention is as follows: a nano-silver nasal cavity nursing sterilizing liquid comprises the following raw material components in parts by weight:
a: 10-20 parts of nano silver particle stock solution (10000 ppm);
b, 3-8 parts of carboxypropyl cellulose;
c: 70-100 parts of deionized water;
d, 3-8 parts of chitosan;
e lecithin6-10 parts;
f, 3-5 parts of glycerol;
the selected A nano silver particles have the following properties:
the silver particles are individually in the range of 2-10nm, wherein at least 80% of the particles have a diameter <5nm and the surface of the silver particles is coated with a dispersing agent.
A preparation method of a nano-silver nasal cavity nursing sterilizing liquid comprises the following steps:
1) Dissolving chitosan (deacetylation > 95%) in purified water, stirring, adding lecithin, dissolving, and standing;
2) And uniformly pouring the commercial nano silver particle solution into the solution, heating to 50-75 ℃, and uniformly stirring.
3) Adding the carboxypropyl cellulose and the glycerol into the solution prepared in the step 2) to ensure that the solution is uniformly dissolved, the solution is clear and viscous, and the solution is light gray.
An application of a nano-silver nasal cavity nursing sterile solution for treating rhinitis.
The application of the nano-silver nasal cavity nursing sterilizing solution comprises the following steps:
the nasal cavity nursing and sterilizing liquid with nano silver is sprayed to nasal cavity to inhale synchronously and smoothly, and then sprayed to the opposite side, wherein adults take the nasal cavity nursing and sterilizing liquid 3-5 times a day, and children take the nasal cavity nursing and sterilizing liquid 2-3 times a day.
The invention has the beneficial effects that: the nasal cavity nursing sterilizing solution adopts nano silver for sterilization, adopts a spraying agent administration mode, directly takes effect aiming at focus, does not need in vivo transformation, and avoids adverse reaction while ensuring curative effect.
Detailed Description
The present invention is further described below with reference to specific embodiments so that those skilled in the art can practice the invention with reference to the description, but the scope of the present invention is not limited to the embodiments of the present invention.
The method is used for forming the implementation of each experiment of the invention, and the invention specifically adopts the following technical scheme:
a nano-silver nasal cavity nursing and sterilizing solution comprises the following raw material components in parts by weight:
a: 18 parts of nano silver particle stock solution (10000 ppm);
b, 5 parts of carboxypropyl cellulose;
c: 85 parts of deionized water;
d, 5 parts of chitosan;
e lecithin9 parts of (1);
f, 3 parts of glycerol;
the selected A nano silver particles have the following properties:
the silver particles are individually in the range of 2-10nm, wherein at least 80% of the particles have a diameter <5nm and the surface of the silver particles is coated with a dispersing agent.
A preparation method of nano-silver nasal cavity care solution comprises the following steps:
3) Dissolving chitosan (deacetylation > 95%) in purified water, stirring, adding lecithin, dissolving, and standing;
4) And uniformly pouring the commercial nano silver particle solution into the solution, heating to 50-75 ℃, and uniformly stirring.
3) Adding the carboxypropyl cellulose and the glycerol into the solution prepared in the step 2) to ensure that the solution is uniformly dissolved, the solution is clear and viscous, and the solution is light gray.
The application of the nano-silver nasal cavity care solution is characterized in that the nano-silver water quality modifier is used for treating rhinitis.
The application of the nano-silver nasal care solution comprises the following steps:
the nasal cavity nursing liquid with nano silver is sprayed to the nasal cavity to inhale synchronously and smoothly, and then sprayed to the opposite side, 3-5 times a day for adults and 2-3 times a day for children.
The results of the application experiments were:
experiment 1:
the observation group randomly selects 60 cases of patients with rhinitis and nasosinusitis, and 20 cases of patients after intranasal endoscopic surgery, inferior turbinate laser surgery and plasma surgery, wherein 80 cases are treated by applying the silver ion antibacterial solution; in the control group, 50 patients suffering from rhinitis and nasosinusitis and 30 patients suffering from nasoscope surgery, inferior turbinate laser and plasma surgery are selected, and in total, 80 patients are simply dripped into the nose by adopting 1% of furol liquid. The age (15 to 62 years), sex and disease condition of the patients in the 2 groups are statistically processed, and the difference has no statistical significance (P < 0.05).
The method comprises the following steps: the observation group used silver ion antibacterial solution to spray the nose, and then the silver ion antibacterial solution was sprayed to the opposite side after the observation group was calmly or easily and synchronously inhaling. The medicine is used for 3~5 times a day for adults, 2-3 times a day for children, and the nasal spraying time or times can be controlled according to the condition of the patient, but the nasal spraying times are all within 6 times a day. 1 treatment course comprises 1 week of treatment; control group: the nasal drops are prepared by dripping 1% of benfuresate solution into the nose, 4-5 times per day.
And (3) judging the clinical curative effect: the components of the rhinitis and the nasosinusitis have obvious effects, effectiveness and ineffectiveness. (1) effect-showing: nasal congestion, headache symptoms and signs were significantly altered, but paranasal sinus swatches Dou Na were shaded pale or disappeared. (2) effective: the clinical symptoms and signs are obviously changed, but the paranasal sinus radiograph changes little. (3) And (4) invalidation: no obvious change in symptoms and signs. Patients after the nasal endoscopic surgery, the inferior turbinate laser surgery and the plasma surgery only judge effectiveness and ineffectiveness, the nasal cavity ventilation is improved, the patients with the edema of the nasal mucosa relieved are effective, and otherwise, the patients with the edema of the nasal mucosa relieved are ineffective.
As a result: the silver ion antibacterial solution is used for treating 20 cases of patients after nasal endoscopic surgery, inferior turbinate laser and plasma surgery; the pure application of the furosin liquid to the treatment after the nasal endoscopic surgery, the inferior turbinate laser and the plasma surgery is effective, but the effect is not as obvious as the application of the silver ion antibacterial solution, and partial patients have nasal irritation and stinging sensation and cannot tolerate the treatment. Particularly, the recovery of nasal mucosa has obvious difference, and most patients need to be matched with antibiotics for application. The results of the treatment of rhinitis and sinusitis in two groups of patients are shown in table 1.
TABLE 1 comparison of the results of treatment of rhinitis and sinusitis in two groups of patients [ n (%) ]
The table 1 shows that the nano-silver nasal cavity nursing and sterilizing solution is an effective medicament for treating rhinitis and nasosinusitis, has the total effective rate of 96.7 percent, has good effect on recovery after nasal cavity operation and laser and plasma treatment, and has better curative effect than a control group. The nano-silver antibacterial solution adopts a spray administration mode, directly takes effect on focus, does not need in vivo conversion, and avoids adverse reaction. Has no obvious adverse reaction in clinical use, and is also suitable for children.
Claims (4)
1. The nano-silver nasal cavity nursing and sterilizing solution is characterized by comprising the following raw material components in parts by weight:
a: 10-20 parts of nano silver particle stock solution (10000 ppm);
b, 3-8 parts of carboxypropyl cellulose;
c: 70-100 parts of deionized water;
d, 3-8 parts of chitosan;
e, 6-10 parts of lecithin;
f, 3-5 parts of glycerol;
the selected A nano silver particles have the following properties:
the silver particles are between 2 and 10nm, wherein at least 80 percent of the particles have a diameter less than 5nm, and the surfaces of the silver particles are coated with the dispersing agent.
2. A preparation method of a nano-silver nasal cavity nursing and sterilizing solution is characterized by comprising the following steps:
dissolving chitosan (deacetylation is more than 95%) in purified water, stirring fully, adding lecithin, dissolving uniformly, and standing for use;
uniformly pouring the commercialized nano silver particle solution into the solution, heating to 50-75 ℃, and uniformly stirring;
3) Adding the carboxypropyl cellulose and the glycerol into the solution prepared in the step 2), ensuring that the solution is dissolved uniformly, the solution is clear and viscous, and the solution is light gray.
3. The application of the nano-silver nasal cavity nursing sterilizing solution is characterized in that the nano-silver water quality modifier is used for treating rhinitis.
4. The application of the nano-silver nasal cavity care and sterilization solution as claimed in claim 3, wherein the application is carried out by adopting the following steps:
the nasal cavity nursing and sterilizing liquid with nano silver is sprayed to nasal cavity to inhale synchronously and smoothly, and then sprayed to the opposite side, wherein adults take the nasal cavity nursing and sterilizing liquid 3-5 times a day, and children take the nasal cavity nursing and sterilizing liquid 2-3 times a day.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210912990.0A CN115414325A (en) | 2022-07-31 | 2022-07-31 | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210912990.0A CN115414325A (en) | 2022-07-31 | 2022-07-31 | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115414325A true CN115414325A (en) | 2022-12-02 |
Family
ID=84196538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210912990.0A Withdrawn CN115414325A (en) | 2022-07-31 | 2022-07-31 | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115414325A (en) |
-
2022
- 2022-07-31 CN CN202210912990.0A patent/CN115414325A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6768733B2 (en) | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | |
| ES2263643T3 (en) | USE OF HYDROXYETHYRUTOSIDS FOR THE TREATMENT OF SYMPTOMS OF THE COMMON CHILLED RH, OF HAY FEVER AND OF INFECTIONS RELATED TO RESPIRATORY TOUCH. | |
| KR101312311B1 (en) | Nasal pharmaceutical formulations and methods of using the same | |
| US20040235807A1 (en) | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea | |
| WO2003020219A2 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| AU2002361918A1 (en) | Aerosolized decongestants for the treatment of sinusitis | |
| US5508282A (en) | Composition and method for treating acute or chronic rhinosinusitis | |
| TW201016209A (en) | Intranasal compositions, dosage forms and methods of treatments | |
| US20090182055A1 (en) | Fungicidal agent containing n-chlorotaurine and use thereof | |
| KR20060003009A (en) | Nasal pharmaceutical formulations and methods of using the same | |
| Sanchez-Gonzalez et al. | A randomized controlled pilot trial to test the efficacy of intranasal chlorpheniramine maleate with xylitol for the treatment of allergic rhinitis | |
| AU2015292258A1 (en) | Compositions and methods of use | |
| CN108721329B (en) | Nursing liquid for relieving rhinitis and preparation method thereof | |
| CN115414325A (en) | Nano-silver nasal cavity nursing and sterilizing solution and preparation method and application thereof | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| CN111840226B (en) | Medicine for treating allergic rhinitis and preparation method thereof | |
| CN115671291A (en) | Atomizing agent and atomizing agent concentrated solution based on G-type brown alginate oligosaccharides as well as preparation methods and applications of atomizing agent and atomizing agent concentrated solution | |
| US20220193174A1 (en) | Nasal spray for preventing influenza based on red pepper extract and heparin and preparation method thereof | |
| CA2852591C (en) | Vitamin d3 compositions and uses thereof for the treatment of nasal passages | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN102579579B (en) | Medicine composition for anaesthetic pain relief after crissum operation | |
| CN111388571A (en) | Compound essential oil for treating rhinitis and cold | |
| WO2019096144A1 (en) | Use of pientzhuang and preparation thereof in treatment of cerebral stroke sequelae | |
| CN108434203A (en) | A kind of Chinese medicine ointment and its preparation method and application for treating nasal polyp | |
| CN114767630A (en) | Medicine composition for treating allergic rhinitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20221202 |
|
| WW01 | Invention patent application withdrawn after publication |